Patent ID: 8337844

Claim:
A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide, the combination being selected from the group consisting of: (a) a combination of a modified 2B8 antibody heavy chain variable region polypeptide having the amino acid residue sequence of SEQ ID NO: 48 and which includes at least one of the following amino acid residues: K at residue 12, P at residue 14, V at residue 20, T at residue 48, T at residue 68, E at residue 82, R at residue 87, T at residue 91, and W at residue 106; and a modified 2B8 antibody light chain variable region polypeptide having the amino acid residue sequence of SEQ ID NO: 49 and which includes at least one of the following amino acid residues: I at residue 11, T at residue 12, T at residue 27, A at residue 29, T at residue 40, S at residue 59, T at residue 69, M at residue 72, S at residue 76, and L at residue 77; and (b) a combination of a modified Leu16 antibody heavy chain variable region polypeptide having the amino acid residue sequence of SEQ ID NO: 50 and which includes at least one of the following amino acid residues: K at residue 12, V at residue 20, T at residue 68, E at residue 82, R at residue 87, T at residue 91, V at residue 93, and T at residue 114; and a modified Leu16 antibody light chain variable region polypeptide having the amino acid residue sequence of SEQ ID NO: 51 and which includes at least one of the following amino acid residues: I at residue 11, T at residue 12, S at residue 59, T at residue 69, M at residue 72, S at residue 76, and L at residue 77.